Pharmacokinetic Profile of Intramuscular Fulvestrant in Advanced Breast Cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2004-07

AUTHORS

John F.R. Robertson, Bjorn Erikstein, Kent C. Osborne, John Pippen, Steven E. Come, Leroy M. Parker, Stan Gertler, Mike P. Harrison, David A. Clarke

ABSTRACT

OBJECTIVE: To characterise the pharmacokinetics of a long-acting formulation of fulvestrant following intramuscular administration of single and multiple doses. STUDY DESIGN: Pharmacokinetic investigations of single and multiple doses of fulvestrant were conducted within two global phase III efficacy studies that compared intramuscular fulvestrant with oral anastrozole in postmenopausal women with hormone-sensitive advanced breast cancer (study 0020, conducted in Europe, Australia and South Africa, and study 0021, conducted in North America). METHODS: Patients received once-monthly intramuscular injections of fulvestrant 250 mg (1 x 5 mL for < or =21 months in study 0020; 2 x 2.5 mL for < or =30 months in study 0021). Serial blood samples were collected for the first 28 days after the initial dose and immediately prior to all subsequent monthly doses. Plasma fulvestrant concentrations were determined by high-performance liquid chromatography-tandem mass spectrometry. PATIENTS: Twenty-six (study 0020) and 193 (study 0021) postmenopausal women, comprising the pharmacokinetic subgroups of the phase III efficacy trials, were studied. Patients had shown disease progression or recurrence following previous hormonal therapy for advanced disease or had relapsed after adjuvant endocrine therapy with a nonsteroidal antiestrogen. OUTCOME MEASURES AND RESULTS: For single-dose fulvestrant 250 mg, area under the concentration-time curve from time zero to 28 days (AUC(28)), maximum observed plasma concentration (C(max)), minimum observed plasma concentration at 28 days (C(min)) and time to maximum plasma concentration (t(max)) were determined. For multiple-dose fulvestrant 250 mg once monthly, steady-state trough concentrations (C(trough)) were determined. Plasma fulvestrant concentrations reached a peak at a median of 7 days (range 2-8 days) postdose, and declined biexponentially with a slower phase commencing approximately 2-3 weeks postdose. Intersubject variability in C(max) and AUC(28) was approximately 6-fold and 4-fold, respectively. Mean parameters for single-dose fulvestrant were: AUC(28), 148 microg. day/L; C(max), 8.2 microg/L; C(min), 2.6 microg/L; t(max), 7.0 days. Geometric mean C(trough) increased from 2.57 to 6.15 microg/L (study 0020) and from 2.38 to 6.52 microg/L (study 0021) over the first 6 months, reaching steady-state concentrations of approximately 6-7 microg/L (study 0020) or 9 microg/L (study 0021). Preliminary pharmacokinetic analysis, using a naive pooled data approach, suggests that observed single- and multiple-dose plasma profiles can be adequately described with a two-compartment kinetic model. Model-generated steady-state AUC(28) values were approximately 300 microg. day/L. CONCLUSIONS: The intramuscular formulation of fulvestrant displays predictable kinetics and approximately 2-fold accumulation on administration once monthly. At the proposed therapeutic dosage (250 mg once monthly), plasma fulvestrant concentrations are maintained within a narrow range throughout the administration interval, thus ensuring stable systemic drug exposure during long-term treatment. More... »

PAGES

529-538

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00003088-200443080-00003

DOI

http://dx.doi.org/10.2165/00003088-200443080-00003

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1022973683

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15170367


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Hormonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Area Under Curve", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Estradiol", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Estrogen Antagonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fulvestrant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Half-Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Metabolic Clearance Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Postmenopause", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Nottingham City Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412920.c", 
          "name": [
            "Nottingham City Hospital, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Robertson", 
        "givenName": "John F.R.", 
        "id": "sg:person.07764637207.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07764637207.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Radium Hospital, Oslo, Norway"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Erikstein", 
        "givenName": "Bjorn", 
        "id": "sg:person.01325122166.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01325122166.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Baylor College of Medicine", 
          "id": "https://www.grid.ac/institutes/grid.39382.33", 
          "name": [
            "Baylor College of Medicine, Houston, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Osborne", 
        "givenName": "Kent C.", 
        "id": "sg:person.010443332235.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010443332235.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Texas Oncology", 
          "id": "https://www.grid.ac/institutes/grid.477898.d", 
          "name": [
            "Texas Oncology, Dallas, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pippen", 
        "givenName": "John", 
        "id": "sg:person.01102571263.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102571263.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Beth Israel Deaconess Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.239395.7", 
          "name": [
            "Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Come", 
        "givenName": "Steven E.", 
        "id": "sg:person.01236610325.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236610325.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dana\u2013Farber Cancer Institute", 
          "id": "https://www.grid.ac/institutes/grid.65499.37", 
          "name": [
            "Dana-Farber Cancer Institute, Boston, Massachusetts, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Parker", 
        "givenName": "Leroy M.", 
        "id": "sg:person.01370754711.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01370754711.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ottawa Regional Cancer Foundation", 
          "id": "https://www.grid.ac/institutes/grid.419945.4", 
          "name": [
            "Ottawa Regional Cancer Center, Ottawa, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gertler", 
        "givenName": "Stan", 
        "id": "sg:person.01230721252.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230721252.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca Pharmaceuticals, Mereside, Alderley Park, SK10 4TG, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Harrison", 
        "givenName": "Mike P.", 
        "id": "sg:person.0635016152.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635016152.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca Pharmaceuticals, Mereside, Alderley Park, SK10 4TG, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clarke", 
        "givenName": "David A.", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1002/1097-0142(20000815)89:4<817::aid-cncr14>3.0.co;2-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009493797"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1996.357", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012787769", 
          "https://doi.org/10.1038/bjc.1996.357"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1996.357", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012787769", 
          "https://doi.org/10.1038/bjc.1996.357"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-200161060-00013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031434257", 
          "https://doi.org/10.2165/00003495-200161060-00013"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-200161060-00013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031434257", 
          "https://doi.org/10.2165/00003495-200161060-00013"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.10.057", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203147"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.10.058", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203148"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/edrv-11-4-578", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064237930"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074686212", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077661065", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083285163", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2004-07", 
    "datePublishedReg": "2004-07-01", 
    "description": "OBJECTIVE: To characterise the pharmacokinetics of a long-acting formulation of fulvestrant following intramuscular administration of single and multiple doses.\nSTUDY DESIGN: Pharmacokinetic investigations of single and multiple doses of fulvestrant were conducted within two global phase III efficacy studies that compared intramuscular fulvestrant with oral anastrozole in postmenopausal women with hormone-sensitive advanced breast cancer (study 0020, conducted in Europe, Australia and South Africa, and study 0021, conducted in North America).\nMETHODS: Patients received once-monthly intramuscular injections of fulvestrant 250 mg (1 x 5 mL for < or =21 months in study 0020; 2 x 2.5 mL for < or =30 months in study 0021). Serial blood samples were collected for the first 28 days after the initial dose and immediately prior to all subsequent monthly doses. Plasma fulvestrant concentrations were determined by high-performance liquid chromatography-tandem mass spectrometry.\nPATIENTS: Twenty-six (study 0020) and 193 (study 0021) postmenopausal women, comprising the pharmacokinetic subgroups of the phase III efficacy trials, were studied. Patients had shown disease progression or recurrence following previous hormonal therapy for advanced disease or had relapsed after adjuvant endocrine therapy with a nonsteroidal antiestrogen.\nOUTCOME MEASURES AND RESULTS: For single-dose fulvestrant 250 mg, area under the concentration-time curve from time zero to 28 days (AUC(28)), maximum observed plasma concentration (C(max)), minimum observed plasma concentration at 28 days (C(min)) and time to maximum plasma concentration (t(max)) were determined. For multiple-dose fulvestrant 250 mg once monthly, steady-state trough concentrations (C(trough)) were determined. Plasma fulvestrant concentrations reached a peak at a median of 7 days (range 2-8 days) postdose, and declined biexponentially with a slower phase commencing approximately 2-3 weeks postdose. Intersubject variability in C(max) and AUC(28) was approximately 6-fold and 4-fold, respectively. Mean parameters for single-dose fulvestrant were: AUC(28), 148 microg. day/L; C(max), 8.2 microg/L; C(min), 2.6 microg/L; t(max), 7.0 days. Geometric mean C(trough) increased from 2.57 to 6.15 microg/L (study 0020) and from 2.38 to 6.52 microg/L (study 0021) over the first 6 months, reaching steady-state concentrations of approximately 6-7 microg/L (study 0020) or 9 microg/L (study 0021). Preliminary pharmacokinetic analysis, using a naive pooled data approach, suggests that observed single- and multiple-dose plasma profiles can be adequately described with a two-compartment kinetic model. Model-generated steady-state AUC(28) values were approximately 300 microg. day/L.\nCONCLUSIONS: The intramuscular formulation of fulvestrant displays predictable kinetics and approximately 2-fold accumulation on administration once monthly. At the proposed therapeutic dosage (250 mg once monthly), plasma fulvestrant concentrations are maintained within a narrow range throughout the administration interval, thus ensuring stable systemic drug exposure during long-term treatment.", 
    "genre": "research_article", 
    "id": "sg:pub.10.2165/00003088-200443080-00003", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1085321", 
        "issn": [
          "0312-5963", 
          "1179-1926"
        ], 
        "name": "Clinical Pharmacokinetics", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "43"
      }
    ], 
    "name": "Pharmacokinetic Profile of Intramuscular Fulvestrant in Advanced Breast Cancer", 
    "pagination": "529-538", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "6d73d97517856c925d0a9f8e17a1889bf54ad004f9de51395acf0e85bfc616f9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15170367"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7606849"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00003088-200443080-00003"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1022973683"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00003088-200443080-00003", 
      "https://app.dimensions.ai/details/publication/pub.1022973683"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:40", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000363_0000000363/records_70053_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.2165/00003088-200443080-00003"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00003088-200443080-00003'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00003088-200443080-00003'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00003088-200443080-00003'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00003088-200443080-00003'


 

This table displays all metadata directly associated to this object as RDF triples.

230 TRIPLES      21 PREDICATES      53 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00003088-200443080-00003 schema:about N0732fad6465449aab0cb095e97c84d9b
2 N0a080b1f276b436f94f353c49cb9ef01
3 N1ae7ea958d0f48cb850d49554afd873f
4 N2ed9b551238b4c5d82aabd4520c2869a
5 N35fa21b2ee944d07bf4be81170013b3c
6 N66ca80eb347c44d7ba9b44396967b498
7 N6b7711efeddb4e9f88030cf7d3c94378
8 N979b734234fc43d9a99334a68eb91c1b
9 N9bcc2280764f4026a838aba62f78bd89
10 Naae127f39eb94dc9a5958d143e3d0cfe
11 Nb1a7e958e6084dc886109cbde20f0d33
12 Nc5ba86ca547d431e98cc0555a495f57a
13 Ndc9c45e5422142d0ae6d6979fe100287
14 Ne0df5884b151414190627969b69cdae5
15 Nf888eabfb7ca4e1b9e1d81f099261221
16 anzsrc-for:11
17 anzsrc-for:1103
18 schema:author N55c6918e34bc4fbb9db6fb11dc7922cd
19 schema:citation sg:pub.10.1038/bjc.1996.357
20 sg:pub.10.2165/00003495-200161060-00013
21 https://app.dimensions.ai/details/publication/pub.1074686212
22 https://app.dimensions.ai/details/publication/pub.1077661065
23 https://app.dimensions.ai/details/publication/pub.1083285163
24 https://doi.org/10.1002/1097-0142(20000815)89:4<817::aid-cncr14>3.0.co;2-6
25 https://doi.org/10.1200/jco.2002.10.057
26 https://doi.org/10.1200/jco.2002.10.058
27 https://doi.org/10.1210/edrv-11-4-578
28 schema:datePublished 2004-07
29 schema:datePublishedReg 2004-07-01
30 schema:description OBJECTIVE: To characterise the pharmacokinetics of a long-acting formulation of fulvestrant following intramuscular administration of single and multiple doses. STUDY DESIGN: Pharmacokinetic investigations of single and multiple doses of fulvestrant were conducted within two global phase III efficacy studies that compared intramuscular fulvestrant with oral anastrozole in postmenopausal women with hormone-sensitive advanced breast cancer (study 0020, conducted in Europe, Australia and South Africa, and study 0021, conducted in North America). METHODS: Patients received once-monthly intramuscular injections of fulvestrant 250 mg (1 x 5 mL for < or =21 months in study 0020; 2 x 2.5 mL for < or =30 months in study 0021). Serial blood samples were collected for the first 28 days after the initial dose and immediately prior to all subsequent monthly doses. Plasma fulvestrant concentrations were determined by high-performance liquid chromatography-tandem mass spectrometry. PATIENTS: Twenty-six (study 0020) and 193 (study 0021) postmenopausal women, comprising the pharmacokinetic subgroups of the phase III efficacy trials, were studied. Patients had shown disease progression or recurrence following previous hormonal therapy for advanced disease or had relapsed after adjuvant endocrine therapy with a nonsteroidal antiestrogen. OUTCOME MEASURES AND RESULTS: For single-dose fulvestrant 250 mg, area under the concentration-time curve from time zero to 28 days (AUC(28)), maximum observed plasma concentration (C(max)), minimum observed plasma concentration at 28 days (C(min)) and time to maximum plasma concentration (t(max)) were determined. For multiple-dose fulvestrant 250 mg once monthly, steady-state trough concentrations (C(trough)) were determined. Plasma fulvestrant concentrations reached a peak at a median of 7 days (range 2-8 days) postdose, and declined biexponentially with a slower phase commencing approximately 2-3 weeks postdose. Intersubject variability in C(max) and AUC(28) was approximately 6-fold and 4-fold, respectively. Mean parameters for single-dose fulvestrant were: AUC(28), 148 microg. day/L; C(max), 8.2 microg/L; C(min), 2.6 microg/L; t(max), 7.0 days. Geometric mean C(trough) increased from 2.57 to 6.15 microg/L (study 0020) and from 2.38 to 6.52 microg/L (study 0021) over the first 6 months, reaching steady-state concentrations of approximately 6-7 microg/L (study 0020) or 9 microg/L (study 0021). Preliminary pharmacokinetic analysis, using a naive pooled data approach, suggests that observed single- and multiple-dose plasma profiles can be adequately described with a two-compartment kinetic model. Model-generated steady-state AUC(28) values were approximately 300 microg. day/L. CONCLUSIONS: The intramuscular formulation of fulvestrant displays predictable kinetics and approximately 2-fold accumulation on administration once monthly. At the proposed therapeutic dosage (250 mg once monthly), plasma fulvestrant concentrations are maintained within a narrow range throughout the administration interval, thus ensuring stable systemic drug exposure during long-term treatment.
31 schema:genre research_article
32 schema:inLanguage en
33 schema:isAccessibleForFree false
34 schema:isPartOf N2d4fdf48f8054d72b8ece8a6eff45aaf
35 N401f2dabe53d4d22b37276a22e9d238f
36 sg:journal.1085321
37 schema:name Pharmacokinetic Profile of Intramuscular Fulvestrant in Advanced Breast Cancer
38 schema:pagination 529-538
39 schema:productId N1c322b5e469143f0b90e23ddea3a91e6
40 N4bca034e734c49c8b75ba08ef7904bab
41 N5142716b1a7d422eaf9a5c125b85fb8a
42 N5b868f5551074e3b97cb9d56d4776962
43 Nf97ed17292f748cdaf61198e65603ddf
44 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022973683
45 https://doi.org/10.2165/00003088-200443080-00003
46 schema:sdDatePublished 2019-04-11T12:40
47 schema:sdLicense https://scigraph.springernature.com/explorer/license/
48 schema:sdPublisher Na3940cf0620046098c9f542e89096791
49 schema:url http://link.springer.com/10.2165/00003088-200443080-00003
50 sgo:license sg:explorer/license/
51 sgo:sdDataset articles
52 rdf:type schema:ScholarlyArticle
53 N0732fad6465449aab0cb095e97c84d9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
54 schema:name Adult
55 rdf:type schema:DefinedTerm
56 N0a080b1f276b436f94f353c49cb9ef01 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
57 schema:name Fulvestrant
58 rdf:type schema:DefinedTerm
59 N14bbe4c2a42946fb9cf857bc509e508f schema:name Radium Hospital, Oslo, Norway
60 rdf:type schema:Organization
61 N1ae7ea958d0f48cb850d49554afd873f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
62 schema:name Aged
63 rdf:type schema:DefinedTerm
64 N1c322b5e469143f0b90e23ddea3a91e6 schema:name pubmed_id
65 schema:value 15170367
66 rdf:type schema:PropertyValue
67 N2d4fdf48f8054d72b8ece8a6eff45aaf schema:issueNumber 8
68 rdf:type schema:PublicationIssue
69 N2ed9b551238b4c5d82aabd4520c2869a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Metabolic Clearance Rate
71 rdf:type schema:DefinedTerm
72 N2f0d7205ef654a9787f186a22625cf92 rdf:first sg:person.0635016152.94
73 rdf:rest Nb4558321ac9b4c9fa8d384c457788d82
74 N35fa21b2ee944d07bf4be81170013b3c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Breast Neoplasms
76 rdf:type schema:DefinedTerm
77 N401f2dabe53d4d22b37276a22e9d238f schema:volumeNumber 43
78 rdf:type schema:PublicationVolume
79 N4bca034e734c49c8b75ba08ef7904bab schema:name doi
80 schema:value 10.2165/00003088-200443080-00003
81 rdf:type schema:PropertyValue
82 N5142716b1a7d422eaf9a5c125b85fb8a schema:name readcube_id
83 schema:value 6d73d97517856c925d0a9f8e17a1889bf54ad004f9de51395acf0e85bfc616f9
84 rdf:type schema:PropertyValue
85 N55c6918e34bc4fbb9db6fb11dc7922cd rdf:first sg:person.07764637207.20
86 rdf:rest N6fc7da9b6fd84ad5b901e59980747d98
87 N5b868f5551074e3b97cb9d56d4776962 schema:name nlm_unique_id
88 schema:value 7606849
89 rdf:type schema:PropertyValue
90 N66ca80eb347c44d7ba9b44396967b498 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Humans
92 rdf:type schema:DefinedTerm
93 N6b7711efeddb4e9f88030cf7d3c94378 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Half-Life
95 rdf:type schema:DefinedTerm
96 N6fc7da9b6fd84ad5b901e59980747d98 rdf:first sg:person.01325122166.69
97 rdf:rest N94457441f38546dea0d16c6ddaf85827
98 N7da8edcbc1ed4c23a7965dddac36691c rdf:first sg:person.01236610325.74
99 rdf:rest Nc1dc577f866f4602842a0aa72f5d0545
100 N94457441f38546dea0d16c6ddaf85827 rdf:first sg:person.010443332235.31
101 rdf:rest Nec68546fed83403696fc7e84e8fedc07
102 N979b734234fc43d9a99334a68eb91c1b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Estradiol
104 rdf:type schema:DefinedTerm
105 N9bcc2280764f4026a838aba62f78bd89 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Postmenopause
107 rdf:type schema:DefinedTerm
108 Na3940cf0620046098c9f542e89096791 schema:name Springer Nature - SN SciGraph project
109 rdf:type schema:Organization
110 Naae127f39eb94dc9a5958d143e3d0cfe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Estrogen Antagonists
112 rdf:type schema:DefinedTerm
113 Nb1a7e958e6084dc886109cbde20f0d33 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Antineoplastic Agents, Hormonal
115 rdf:type schema:DefinedTerm
116 Nb4558321ac9b4c9fa8d384c457788d82 rdf:first Nb8a640323ad14f9b976662c79f348c79
117 rdf:rest rdf:nil
118 Nb8a640323ad14f9b976662c79f348c79 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
119 schema:familyName Clarke
120 schema:givenName David A.
121 rdf:type schema:Person
122 Nc1dc577f866f4602842a0aa72f5d0545 rdf:first sg:person.01370754711.71
123 rdf:rest Nfd6e5acd6756453fa969dfaad2955243
124 Nc5ba86ca547d431e98cc0555a495f57a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Area Under Curve
126 rdf:type schema:DefinedTerm
127 Ndc9c45e5422142d0ae6d6979fe100287 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Double-Blind Method
129 rdf:type schema:DefinedTerm
130 Ne0df5884b151414190627969b69cdae5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Middle Aged
132 rdf:type schema:DefinedTerm
133 Nec68546fed83403696fc7e84e8fedc07 rdf:first sg:person.01102571263.20
134 rdf:rest N7da8edcbc1ed4c23a7965dddac36691c
135 Nf888eabfb7ca4e1b9e1d81f099261221 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Female
137 rdf:type schema:DefinedTerm
138 Nf97ed17292f748cdaf61198e65603ddf schema:name dimensions_id
139 schema:value pub.1022973683
140 rdf:type schema:PropertyValue
141 Nfd6e5acd6756453fa969dfaad2955243 rdf:first sg:person.01230721252.04
142 rdf:rest N2f0d7205ef654a9787f186a22625cf92
143 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
144 schema:name Medical and Health Sciences
145 rdf:type schema:DefinedTerm
146 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
147 schema:name Clinical Sciences
148 rdf:type schema:DefinedTerm
149 sg:journal.1085321 schema:issn 0312-5963
150 1179-1926
151 schema:name Clinical Pharmacokinetics
152 rdf:type schema:Periodical
153 sg:person.010443332235.31 schema:affiliation https://www.grid.ac/institutes/grid.39382.33
154 schema:familyName Osborne
155 schema:givenName Kent C.
156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010443332235.31
157 rdf:type schema:Person
158 sg:person.01102571263.20 schema:affiliation https://www.grid.ac/institutes/grid.477898.d
159 schema:familyName Pippen
160 schema:givenName John
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102571263.20
162 rdf:type schema:Person
163 sg:person.01230721252.04 schema:affiliation https://www.grid.ac/institutes/grid.419945.4
164 schema:familyName Gertler
165 schema:givenName Stan
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230721252.04
167 rdf:type schema:Person
168 sg:person.01236610325.74 schema:affiliation https://www.grid.ac/institutes/grid.239395.7
169 schema:familyName Come
170 schema:givenName Steven E.
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236610325.74
172 rdf:type schema:Person
173 sg:person.01325122166.69 schema:affiliation N14bbe4c2a42946fb9cf857bc509e508f
174 schema:familyName Erikstein
175 schema:givenName Bjorn
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01325122166.69
177 rdf:type schema:Person
178 sg:person.01370754711.71 schema:affiliation https://www.grid.ac/institutes/grid.65499.37
179 schema:familyName Parker
180 schema:givenName Leroy M.
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01370754711.71
182 rdf:type schema:Person
183 sg:person.0635016152.94 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
184 schema:familyName Harrison
185 schema:givenName Mike P.
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635016152.94
187 rdf:type schema:Person
188 sg:person.07764637207.20 schema:affiliation https://www.grid.ac/institutes/grid.412920.c
189 schema:familyName Robertson
190 schema:givenName John F.R.
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07764637207.20
192 rdf:type schema:Person
193 sg:pub.10.1038/bjc.1996.357 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012787769
194 https://doi.org/10.1038/bjc.1996.357
195 rdf:type schema:CreativeWork
196 sg:pub.10.2165/00003495-200161060-00013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031434257
197 https://doi.org/10.2165/00003495-200161060-00013
198 rdf:type schema:CreativeWork
199 https://app.dimensions.ai/details/publication/pub.1074686212 schema:CreativeWork
200 https://app.dimensions.ai/details/publication/pub.1077661065 schema:CreativeWork
201 https://app.dimensions.ai/details/publication/pub.1083285163 schema:CreativeWork
202 https://doi.org/10.1002/1097-0142(20000815)89:4<817::aid-cncr14>3.0.co;2-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009493797
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1200/jco.2002.10.057 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203147
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1200/jco.2002.10.058 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203148
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1210/edrv-11-4-578 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064237930
209 rdf:type schema:CreativeWork
210 https://www.grid.ac/institutes/grid.239395.7 schema:alternateName Beth Israel Deaconess Medical Center
211 schema:name Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
212 rdf:type schema:Organization
213 https://www.grid.ac/institutes/grid.39382.33 schema:alternateName Baylor College of Medicine
214 schema:name Baylor College of Medicine, Houston, Texas, USA
215 rdf:type schema:Organization
216 https://www.grid.ac/institutes/grid.412920.c schema:alternateName Nottingham City Hospital
217 schema:name Nottingham City Hospital, Nottingham, UK
218 rdf:type schema:Organization
219 https://www.grid.ac/institutes/grid.417815.e schema:alternateName AstraZeneca (United Kingdom)
220 schema:name AstraZeneca Pharmaceuticals, Mereside, Alderley Park, SK10 4TG, Macclesfield, UK
221 rdf:type schema:Organization
222 https://www.grid.ac/institutes/grid.419945.4 schema:alternateName Ottawa Regional Cancer Foundation
223 schema:name Ottawa Regional Cancer Center, Ottawa, Ontario, Canada
224 rdf:type schema:Organization
225 https://www.grid.ac/institutes/grid.477898.d schema:alternateName Texas Oncology
226 schema:name Texas Oncology, Dallas, Texas, USA
227 rdf:type schema:Organization
228 https://www.grid.ac/institutes/grid.65499.37 schema:alternateName Dana–Farber Cancer Institute
229 schema:name Dana-Farber Cancer Institute, Boston, Massachusetts, USA
230 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...